What do systematic reviews say?

CCPT vs ACBT

• Conventional chest physiotherapy compared to other airway clearance techniques for cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Very low

CCPT vs O‐PEP devices

• Conventional chest physiotherapy compared to other airway clearance techniques for cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 155 participants
  Very low

CCPT vs AD

• Conventional chest physiotherapy compared to other airway clearance techniques for cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 36 participants
  Very low

CCPT vs exercise

The review found no eligible studies for this question.

• Conventional chest physiotherapy compared to other airway clearance techniques for cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

CCPT vs PEP

• Conventional chest physiotherapy compared to other airway clearance techniques for cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 224 participants
  Very low

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferoxamine

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 612 participants
  Very low

DFX film‐coated tablet vs DFX dispersible tablet

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 91 participants
  Very low

DFX film‐coated tablet vs DFX dispersible tablet

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 54 participants
  Very low

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferoxamine

It is very uncertain whether summary of findings: Comparison 1 ‐ deferiprone (DFP) changes total reported SAEs (from therapy, disease, non‐adherence) compared with deferoxamine (DFO) (very low certainty).

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  RR 1.43 [0.83, 2.46]
  1 study · 228 participants
  Very low

DFP and DFO vs DFP

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 369 participants
  Low

DFP and DFO vs deferoxamine

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 281 participants
  Low

DFP and DFO vs DFP and DFX

Summary of findings: Comparison 7 ‐ deferiprone (DFP) plus… may leads to lower adherence to iron chelation therapy rates (n, N) compared with DFP plus deferasirox (DFX) (low certainty).

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  RR 0.84 [0.72, 0.99]
  1 study · 96 participants
  Low

Deferasirox vs deferiprone (DFO)

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 452 participants
  Very low

Intervention not reported

The review found no eligible studies for this question.

• First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Amoxicillin + metronidazole + SRP vs Supragingival scaling (plus placebo)

It is very uncertain whether scaling and root planing (SRP) plus antibiotics (amoxicillin and… changes adverse events due to periodontal therapy compared with supragingival scaling (plus placebo) (very low certainty).

• Periodontal therapy for primary or secondary prevention of cardiovascular disease in people with periodontitis 2022 · Cochrane All outcomes

  12 months
  Peto OR 0.14 [0.00, 6.90]
  1 study · 165 participants
  Very low

Active cycle of breathing techniques plus routine treatment vs routine treatment alone

• Chest physiotherapy for pneumonia in adults 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 32 participants
  Very low

Osteopathic manipulative treatment (OMT) plus routine treatment vs placebo plus routine treatment

• Chest physiotherapy for pneumonia in adults 2022 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 333 participants
  Very low

Positive expiratory pressure plus routine treatment vs routine treatment alone

The review found no eligible studies for this question.

• Chest physiotherapy for pneumonia in adults 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

High‐frequency chest wall oscillation plus fibrobronchoscope alveolar lavage vs fibrobronchoscope alveolar lavage alone

The review found no eligible studies for this question.

• Chest physiotherapy for pneumonia in adults 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found